Literature DB >> 10766368

Determination of MAG-camptothecin, a new polymer-bound camptothecin derivative, and free camptothecin in dog plasma by HPLC with fluorimetric detection.

D Fraier1, E Frigerio, G Brianceschi, M Casati, A Benecchi, C James.   

Abstract

A high throughput. selective and sensitive high-performance liquid chromatographic (HPLC) method for the determination of a water-soluble polymer-bound Camptothecin conjugate (MAG-CPT) and Camptothecin (CPT) in dog plasma has been developed and validated. The method involved the analysis of free and total CPT (free + polymer-bound). Free CPT (intact lactone plus carboxylate) was extracted from acidified plasma using Oasis SPE material in 96-well plates. For the assay of the total CPT, plasma proteins were first precipitated with methanol in a 96-well plate containing a 10-microm melt blown polypropylene membrane. The methanolic supernatant was separated and collected into a second 96-well plate by simply applying vacuum to the plate. After hydrolysis at pH 9.8 for 18 h and re-acidification, samples were injected directly from the collection plate onto the HPLC system. MAG-CPT concentration was then calculated by subtraction of free from total CPT. The LLOQs of the method were 1.17 ng/ml for free CPT and 103.10 ng/ml (as CPT equivalent) for MAG-CPT using 0.1 and 0.05 ml of plasma, respectively. Linearity, precision, accuracy and recovery of the method were evaluated. The stability of MAG-CPT in plasma alone and after its stabilisation was carefully evaluated. No interference from blank dog, mouse and human plasma was observed. The suitability of the method for in vivo samples was assessed by the analysis of samples obtained from dogs that had received a single and 5-day repeated dose of MAG-CPT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766368     DOI: 10.1016/s0731-7085(99)00315-5

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

Review 1.  Clinical developments of antitumor polymer therapeutics.

Authors:  Shazia Parveen; Farukh Arjmand; Sartaj Tabassum
Journal:  RSC Adv       Date:  2019-08-08       Impact factor: 4.036

2.  A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours.

Authors:  F M Wachters; H J M Groen; J G Maring; J A Gietema; M Porro; H Dumez; E G E de Vries; A T van Oosterom
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

Review 3.  Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy.

Authors:  Nataša Avramović; Boris Mandić; Ana Savić-Radojević; Tatjana Simić
Journal:  Pharmaceutics       Date:  2020-03-25       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.